People with haemophilia tend to experience pain from an early age because of venipuncture and hemarthrosis. If pain is not properly managed, it can become chronic and bedevil patients throughout their lives. Therapies are currently available that have been shown to effectively treat the different types of pain and their causes. Patients with haemophilia tend to experience either nociceptive or mixed pain. Identification of the cause of pain by means of imaging techniques, and understanding the characteristics, location and intensity of the pain, are essential for a more targeted therapeutic approach. Current data reveal that the most effective measures are administration of haematological and analgesic medication, intraarticular injections, and physical exercise. However, multimodal strategies such as lifestyle changes, physical modalities, psychological support and orthopaedic surgery can also prove of use. This article will look at the most effective analgesic measures used as a part of conservative clinical treatment. Collaborative studies are needed to better understand the nature of pain in the context of haemophilia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MBC.0000000000001199 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical, Laboratory Aspects and Management of Factor X Deficiency.
Semin Thromb Hemost
August 2024
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.
Article Synopsis
- - Coagulation factor X (FX), crucial for blood clotting, activates thrombin and helps prevent excessive bleeding; genetic variants can lead to FX deficiency, which is linked to severe bleeding disorders.
- - FX deficiency can be classified as type I (reduced FX activity and antigen levels) or type II (normal antigen but reduced activity), leading to a variable bleeding tendency that can cause life-threatening symptoms.
- - Treatment for FX deficiency has evolved from traditional methods like fresh frozen plasma to safer plasma-derived concentrates, with emerging therapies like gene therapy and drug repurposing requiring further research.
Glanzmann Thrombasthenia Associated with Siderotic Synovitis and Arthropathy: A Case Report.
J Blood Med
November 2023
Department of Medical Oncology, Hematology and BMT Section, National Center for Hamad Medical Corporation, Doha, Qatar.
Glanzmann thrombasthenia is a bleeding disorder with a low incidence. It typically manifests as superficial bleeding episodes, which tend to be mild. Deep organ involvement is not uncommon but remains rare due to the rarity of the disease itself and the unusual association between platelet disorders and deep organ implications.
View Article and Find Full Text PDFPsychological and cognitive factors involved in decision-making process of haemophilia carriers in reproductive choices.
Haemophilia
September 2023
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, and Fondazione Luigi Villa, Milan, Italy.
Introduction: Haemophilia carriers (HCs) face a multitude of psychological challenges, mainly linked to the possibility of having an affected child. Important reproductive decisions such as opting for pre-implantation genetic testing, or choosing prenatal diagnosis and then whether to continue or interrupt pregnancy in case of affected male fetus, have to be taken into consideration. Notwithstanding, the role of psychological characteristics on such decision-making process needs further investigation.
View Article and Find Full Text PDFBarriers and facilitators of physical activity in adults with severe haemophilia: A qualitative study.
Haemophilia
September 2023
Exercise Intervention for Health Research Group (EXINH-RG), Department of Physiotherapy, University of Valencia, Valencia, Spain.
Background: People with haemophilia (PWH) tend to be less physically active than the general population, but there is a lack of research on the specific barriers and facilitators affecting their participation in physical activities.
Objectives: This study aims to explore perceived barriers and facilitators to physical activity in severe PWH.
Design: An explorative qualitative study based on focus groups.
Longitudinal observations of TFPI levels in paediatric Haemophilia A patients.
Haemophilia
July 2023
Bayer AG, Wuppertal, Germany.
Introduction: Inhibition of tissue factor pathway inhibitor (TFPI) is a potential new mode of action to achieve haemostasis in haemophilia A and B patients.
Aim: Knowledge about potential developmental changes of TFPI levels during childhood are a prerequisite to translate adult doses of TFPI inhibitors to doses in paediatric patients.
Methods: In this study we present longitudinal data for total TFPI concentrations (TFPI-T) and TFPI activity (TFPI-A) from 48 paediatric Haemophilia A patients in the age range from 3 to 18 years (2-12 observations per patient).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!